Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Rix

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Journal of the National Cancer Institute|September 13, 2014
Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposingEric B Haura, Uwe Rix
Nature Chemical Biology|August 20, 2009
Target profiling of small molecules by chemical proteomicsUwe Rix, Giulio Superti-Furga
Nature Chemical Biology|June 27, 2018
Unraveling the rewired networkVinayak Palve, Brent M Kuenzi, Uwe Rix
Methods in Molecular Biology (Clifton, N.J.)|November 9, 2011
Compound immobilization and drug-affinity chromatographyUwe Rix, Manuela Gridling, Giulio Superti-Furga
Leukemia & Lymphoma|April 10, 2008
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinibOliver Hantschel, Uwe Rix, Giulio Superti-Furga
Expert Opinion on Investigational Drugs|February 2, 2010
Dasatinib in solid tumorsLori C Kim, Uwe Rix, Eric B Haura
Expert Review of Proteomics|September 26, 2018
Bidirectional Adaptive Signaling between cancer and stromal cells: mechanisms and therapeuticsM Boutchueng-Djidjou, Uwe Rix, Eric B Haura
Natural Product Reports|November 15, 2002
Modification of post-PKS tailoring steps through combinatorial biosynthesisUwe Rix, Carsten Fischer, Lily L Remsing, et al.
Cancer Immunology Research|June 18, 2015
Charting Immune Signaling Proteomes En Route to New Therapeutic StrategiesEric B Haura, Amer A Beg, Uwe Rix, et al.
Proteomics. Clinical Applications|January 4, 2012
Systems biology analysis of protein-drug interactionsJacques Colinge, Uwe Rix, Keiryn L Bennett, et al.
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Journal of the National Cancer Institute|September 13, 2014
Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposingEric B Haura, Uwe Rix
Nature Chemical Biology|August 20, 2009
Target profiling of small molecules by chemical proteomicsUwe Rix, Giulio Superti-Furga
Nature Chemical Biology|June 27, 2018
Unraveling the rewired networkVinayak Palve, Brent M Kuenzi, Uwe Rix
Methods in Molecular Biology (Clifton, N.J.)|November 9, 2011
Compound immobilization and drug-affinity chromatographyUwe Rix, Manuela Gridling, Giulio Superti-Furga
Leukemia & Lymphoma|April 10, 2008
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinibOliver Hantschel, Uwe Rix, Giulio Superti-Furga
Expert Opinion on Investigational Drugs|February 2, 2010
Dasatinib in solid tumorsLori C Kim, Uwe Rix, Eric B Haura
Expert Review of Proteomics|September 26, 2018
Bidirectional Adaptive Signaling between cancer and stromal cells: mechanisms and therapeuticsM Boutchueng-Djidjou, Uwe Rix, Eric B Haura
Natural Product Reports|November 15, 2002
Modification of post-PKS tailoring steps through combinatorial biosynthesisUwe Rix, Carsten Fischer, Lily L Remsing, et al.
Cancer Immunology Research|June 18, 2015
Charting Immune Signaling Proteomes En Route to New Therapeutic StrategiesEric B Haura, Amer A Beg, Uwe Rix, et al.
Proteomics. Clinical Applications|January 4, 2012
Systems biology analysis of protein-drug interactionsJacques Colinge, Uwe Rix, Keiryn L Bennett, et al.
Pageof 9